MedTrace Logo

Ovarian Clear Cell Adenocarcinoma Review

NCT02129036 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 5

Last updated 2019-08-09

No results posted yet for this study

Summary

Clear cell carcinoma comprises 5-10% of surface epithelial ovarian cancers, and about 30-40% of the patients with clear cell carcinoma are diagnosed in the advanced stage. The investigators studied the response to chemotherapy and survival for either paclitaxel-platinum based chemotherapy or conventional platinum-based chemotherapy among all stages clear cell ovarian carcinoma. Prognostic factors for survival among the patients with pure, advanced, clear cell ovarian carcinoma were also evaluated.

Conditions

  • Ovarian Cysts

Sponsors & Collaborators

  • National Taiwan University Hospital

    collaborator OTHER

  • Cathay General Hospital

    lead OTHER

Principal Investigators

  • Chih-Ming Ho · Gynecologic Cancer Center, Cathay general Hospital

Eligibility

Min Age
30 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2012-12-31
Completion
2013-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02129036 on ClinicalTrials.gov